Post-Marketing Surveillance of Ventavis® in Chinese Patients With Primary Pulmonary Hypertension (PPH)
NCT00882947 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 38
Last updated 2009-04-17
Summary
The purpose of this study is to demonstrate the safety and efficacy of inhaled Iloprost (Ventavis®) among adult Chinese patients with primary pulmonary hypertension, which is in compliance with Chinese SFDA regulation.
Conditions
- Primary Hypertension
Interventions
- DRUG
-
Ventavis (Iloprost, BAYQ6256)
Iloprost solution for inhalation, BAYQ6256, Synthetic Prostacyclin analog
Sponsors & Collaborators
- lead INDUSTRY
Principal Investigators
-
Bayer Study Director · Bayer
Eligibility
- Min Age
- 18 Years
- Max Age
- 65 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2006-02-28
- Primary Completion
- 2008-09-30
- Completion
- 2008-09-30
Countries
- China
More Related Trials
-
Inhaled Iloprost (Ventavis): Efficacy, Safety, and Pharmacokinetics (PK) Confirmation Study
NCT01469169 ·Status: COMPLETED ·Phase: PHASE3
-
Aerosolized Randomized Iloprost Study II (AIR - II) Long-Term Safety, Tolerability, and Clinical Effects of Iloprost Inhalation in Patients With Primary or Secondary Pulmonary Hypertension
NCT00414687 ·Status: COMPLETED ·Phase: PHASE2
-
Non-interventional Study on Compliance of Inhaled Treatment With Ventavis in Patient With Pulmonary Hypertension
NCT01971450 ·Status: COMPLETED
-
Effects of Ventavis in Patients With Pulmonary Hypertension (PH) Secondary to Chronic Obstructive Pulmonary Disease (COPD)
NCT01437878 ·Status: TERMINATED ·Phase: PHASE2
-
Efficacy of Ventavis Used in Real-life Setting.
NCT01355380 ·Status: COMPLETED
-
Inhaled Iloprost in Adults With Abnormal Pulmonary Pressure and Associated With Idiopathic Pulmonary Fibrosis
NCT00109681 ·Status: COMPLETED ·Phase: PHASE2
-
Effect of BMPR-2 Gene Mutations on Hemodynamic Response by Iloprost Inhalation in Pulmonary Arterial Hypertension
NCT01054105 ·Status: COMPLETED
-
Evaluation of Inhaled Iloprost Effects Using the Breelib Nebulizer, on Clinical Outcomes and Physical Activity of Patients With Advanced Pulmonary Arterial Hypertension
NCT03293407 ·Status: COMPLETED
-
Non-interventional Multi-center Study on Patients Under Routine Treatment of Pulmonary Arterial Hypertension (PAH) With Inhaled Iloprost Using I-Neb as a Device for Inhalation
NCT01894035 ·Status: COMPLETED
-
The "VISION" Trial: Ventavis Inhalation With Sildenafil to Improve and Optimize Pulmonary Arterial Hypertension
NCT00302211 ·Status: TERMINATED ·Phase: PHASE3
-
Observational Description of Compliance for the Daily Ventavis Use Via the Insight Program in Class III Pulmonary Arterial Hypertension Patients
NCT01781052 ·Status: COMPLETED
-
Safety and Efficacy of Inhaled Iloprost in Pediatric Patients With Pulmonary Arterial Hypertension
NCT00453414 ·Status: WITHDRAWN ·Phase: PHASE2
-
Ventavis® Registry Protocol
NCT00902603 ·Status: TERMINATED
-
Safety, Pharmacokinetics and Efficacy Study of QCC374 in PAH Patients
NCT02927366 ·Status: TERMINATED ·Phase: PHASE2
-
Study of the Initial Combination of Bosentan With Iloprost in the Treatment of Pulmonary Hypertension Patients
NCT01712997 ·Status: UNKNOWN ·Phase: PHASE3
-
The "Power 15 Study": Safety Study of Inhalation of Ventavis With the Power Disc-15 Setting
NCT00467896 ·Status: TERMINATED ·Phase: PHASE2
-
Educational Training Influence in Patients With PAH(Pulmonary Artery Hypertension) on Inhaled Ventavis Treatment Adherence Evaluated Trough INSIGHT System
NCT01468545 ·Status: COMPLETED
-
A Multinational, Multicenter, Study to Assess the Efficacy and Safety of BPS-314d-MR in Subjects With Pulmonary Arterial Hypertension Currently Receiving Treatment With an Endothelin Receptor Antagonist and/or a Phosphodiesterase-5 Inhibitor
NCT01458236 ·Status: WITHDRAWN ·Phase: PHASE3
-
A Healthy Volunteer Study Evaluating the the Safety, Tolerability, and Pharmacokinetics of RT234
NCT05567367 ·Status: COMPLETED ·Phase: PHASE1
-
Examination of Ventavis (Iloprost) Inhalation Behavior Using the I-Neb AAD System in Patients With Pulmonary Arterial Hypertension When Switching the Iloprost Nebulizer Solution for Inhalation From 10 μg/mL (V10) to 20 μg/mL (V20)
NCT02826252 ·Status: COMPLETED
-
Transitioning To IV Remodulin From Ventavis in Patients With PAH: Safety, Efficacy and Treatment Satisfaction
NCT00458042 ·Status: TERMINATED ·Phase: PHASE4
-
Comparison of Efficacy Different Treatment Regimens in Pulmonary Hypertension Secondary to Lung Disease and or Hypoxia
NCT01449253 ·Status: UNKNOWN ·Phase: PHASE4
-
Safety Surveillance of Targeted Drugs for Pulmonary Hypertension Using a Computerized Follow-up System: a Nationwide Cohort Study
NCT05372263 ·Status: RECRUITING
-
A Research Study To Assess The Effectiveness And Safety Of Different Doses Of Oral PF-00489791 In The Treatment Of Adult Patients With Pulmonary Arterial Hypertension
NCT00853112 ·Status: TERMINATED ·Phase: PHASE2
-
A Dose Escalation Study to Evaluate the Effect of RT234 in Subjects With Pulmonary Arterial Hypertension
NCT05343637 ·Status: COMPLETED ·Phase: PHASE2